A Successful Failure? Lartruvo’s Speedy Withdrawal Sets New Bar For Accelerated Approval Drugs

 
• By Sue Sutter

Lilly withdraws soft tissue sarcoma drug for failure to confirm clinical benefit two and a half years after US FDA awarded accelerated approval, becoming the fastest withdrawal yet under the regulatory pathway.

Close-up Stopwatch in Human Hand, Timer
Lartruvo is the fastest withdrawal of an accelerated approval drug. • Source: Shutterstock

More from Review Pathways

More from Pathways & Standards